OXB Expands AAV Manufacturing with Plowshare Therapies Gene Therapy Deal
- OXB signed a GMP manufacturing agreement with Plowshare Therapies for AAV process development and commercial-scale production of a rare disease gene therapy.
- Work will be performed at OXB's FDA-approved viral vector facility in Durham, North Carolina, with potential to expand to additional programs as Plowshare's pipeline advances.
- The partnership reinforces OXB's strategic position in its global AAV network following the facility's acquisition in October 2025.
Operational Impact
OXB's Durham AAV facility now anchors commercial-scale gene therapy manufacturing for Plowshare, demonstrating post-acquisition capacity utilization and positioning the site as a hub within OXB's expanded US viral vector network.
Source: PharmaSource RSS